Check for updates

REVIEW

Genetic investigation of childhood vascular tumor biology reveals pathways for therapeutic intervention [version 1; peer review: 2 approved]

Shayan Cheraghlou ¹⁻³, Young Lim¹⁻³, Keith Choate ¹⁻³

¹Department of Dermatology, Yale School of Medicine, New Haven, CT, USA

²Department of Pathology, Yale School of Medicine, New Haven, CT, USA

³Department of Genetics, Yale School of Medicine, New Haven, CT, USA

V1 First published: 30 Apr 2019, 8(F1000 Faculty Rev):590
<https://doi.org/10.12688/f1000research.16160.1>

Latest published: 30 Apr 2019, 8(F1000 Faculty Rev):590
<https://doi.org/10.12688/f1000research.16160.1>

Abstract

Vascular tumors are neoplasms of endothelial cells, a significant number of which present in childhood. Recent studies have examined the mutational landscape of many subtypes of vascular tumors, identifying mutations primarily within the Ras-mitogen-activated protein kinase (MAPK) pathway and providing a unique opportunity to consider targeted therapeutics. This review will summarize the current understanding of childhood vascular tumor pathobiology.

Keywords

vascular tumors; vascular tumor management; genetics; hemangioma; Ras; MAPK; GNA14; GNA11; GNAQ; IDH

Open Peer Review

Approval Status

	1	2
version 1
30 Apr 2019		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Joyce Bischoff**, Boston Children's Hospital, Harvard Medical School, Boston, USA
2. **Douglas A. Marchuck**, Duke University Medical Center, Durham, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Keith Choate (keith.choate@yale.edu)

Author roles: Cheraghlou S: Conceptualization, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Lim Y: Conceptualization, Visualization, Writing – Review & Editing; Choate K: Conceptualization, Project Administration, Resources, Supervision, Visualization, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The work for this report was supported by the Leon Rosenberg, M.D., Medical Student Research Fund in Genetics and the Jane Danowski Weiss Family Foundation Fellowship at the Yale University School of Medicine.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Cheraghlou S *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Cheraghlou S, Lim Y and Choate K. **Genetic investigation of childhood vascular tumor biology reveals pathways for therapeutic intervention [version 1; peer review: 2 approved]** F1000Research 2019, 8(F1000 Faculty Rev):590 <https://doi.org/10.12688/f1000research.16160.1>

First published: 30 Apr 2019, 8(F1000 Faculty Rev):590 <https://doi.org/10.12688/f1000research.16160.1>

Introduction

Vascular anomalies are divided into two groups: malformations and tumors¹. The most recent International Society for the Study of Vascular Anomalies (ISSVA) classification for vascular tumors further subdivides them into three primary groups: benign tumors, locally aggressive or borderline tumors, and malignant tumors (Table 1).

Infantile hemangiomas

Infantile hemangioma (IH) is the most common childhood vascular neoplasm; IH has an incidence of approximately 4.5% by 3 months of age². However, the genetic mechanism of IH pathobiology remains unknown despite its prevalence. In 1999, Walter *et al.* mapped a familial form of IH to 5q31-33, housing three candidate genes—fibroblast growth factor receptor-4 (*FGFR4*), platelet-derived growth factor receptor- β (*PDGF- β*), and fms-related tyrosine kinase-4 (*FLT4*)³—and in subsequent work found that a small number of IHs (2 out of 15 studied cases) harbor somatic mutations in vascular endothelial growth factor (*VEGF*)-receptor 2 (p.P1147S) and *VEGFR3* (p.P954S) (also known as *FLT4*)⁴. Nonetheless, these variants have yet to be confirmed via *in vitro* or *in vivo* studies to cause vascular tumors or oncogenic transformation. However, a recent single-nucleotide polymorphism (SNP) study of *VEGFR-2* and *VEGF-A* in IH was unable to detect variants associated with disease, although the G allele of rs2010963 in *VEGF-A* was associated

with a significantly lower risk of IH⁵. Additionally, there is some debate regarding the sporadic or familial etiology of IH. Whereas twin studies suggest extra-genetic factors as the primary cause of disease, recent work studying multiple pedigrees suggests an either autosomal dominant or maternally transmitted inheritance pattern^{6,7}. Genetic analysis of syndromic forms of IH, including PHACE syndrome (posterior fossa malformations, infantile hemangiomas, arterial anomalies, cardiac defects, and eye anomalies syndrome), which appears more often in female offspring, suggests a possible X-linked recessive pattern but has not identified a somatic mutation associated with most cases^{8–10}. Similarly, a causative mutation has not yet been identified in LUMBAR syndrome (lower body hemangioma, urogenital malformation, myelopathy, bony deformities, anorectal malformations, arterial anomalies, and renal anomalies syndrome)¹¹. The three leading hypotheses on the pathogenesis of IH are (1) local hypoxemia leading to hypoxia-inducible factor 1 alpha (HIF-1 α)-induced proliferation^{12,13}, (2) embolization of placental cells^{14–17}, and (3) vasculogenesis/angiogenesis driven by hypoxemia-induced differentiation of mesenchymal stem cells into endothelial cells and Notch-mediated differentiation of mesenchymal stem cells into proangiogenic pericytes^{18–22}. These hypotheses do not address the multi-system defects found in PHACE or LUMBAR syndromes which suggest that somatic mosaicism plays a role in pathogenesis.

Table 1. International Society for the Study of Vascular Anomalies (ISSVA) classification of vascular tumors²³.

Benign vascular tumors	Infantile hemangiomas
	Congenital hemangioma (CH)
	Rapidly involuting CH
	Non-involuting CH
	Partially involuting CH
	Tufted angioma
	Spindle cell hemangioma
	Epithelioid hemangioma
	Lobular capillary hemangiomas (pyogenic granuloma)
	Others
Locally aggressive or borderline vascular tumors	Kaposiform hemangioendothelioma
	Retiform hemangioendothelioma
	Papillary intralymphatic angioendothelioma
	Composite hemangioendothelioma
	Pseudomyogenic hemangioendothelioma
	Polymorphous hemangioendothelioma
	Hemangioendothelioma and not otherwise specified
	Kaposi sarcoma
	Others
Malignant vascular tumors	Angiosarcoma
	Epithelioid hemangioendothelioma
	Others

Unlike other childhood vascular tumors, IH responds to beta-blockers; 60% of patients experience complete or near-complete resolution of the lesion and 88% of patients demonstrate improvement following a 6-month course of propranolol at a dose of 3 mg/kg per day²⁴. Prior to the advent of beta-blockers in the treatment of IH, treatment with systemic corticosteroids was considered the standard of care, and a pooled meta-analysis estimated that 69% of lesions respond to therapy²⁵, although significant morbidity—including Cushingoid features, gastroesophageal reflux, hypertension, ulceration, bleeding, failure to thrive, hirsutism, hypercholesterolemia, and infection—was also reported^{26,27}. IH can also be distinguished from other tumors by its positive GLUT1 immunoreactivity; up to 97% of lesions show positive signal^{17,28}. Notably, however, about half of the vessels in a given tumor are GLUT1-negative, suggesting that a heterogeneous population of endothelial cells populates these lesions, an idea later confirmed by *in vitro* studies of cells isolated from IH samples^{17,29}. Although the genetic factors contributing to IH pathobiology remain unknown, many somatic mutations associated with GLUT1-negative vascular tumors have been identified in recent years, most in genes already known to be implicated in tumorigenesis.

IDH1/IDH2

Genetic insight into spindle cell hemangiomas (SCHs) came from studies of Maffucci syndrome (Spranger type II enchondromatosis), a subtype of enchondromatosis presenting with multiple SCHs in early childhood³⁰. In an analysis of 13 patients with Maffucci syndrome, Pansuriya *et al.* found that 70% of SCHs had p.R132C mutations in exon 4 of isocitrate dehydrogenase 1 (*IDH1*)³¹. Given the disorder's unilateral distribution of the enchondromas, the lack of mutations detected in adjacent non-lesional tissue, the absence of transmission within pedigrees, and the identification of tissue-specific *IDH1* mutations, somatic mosaicism was considered causal. Further work in sporadic, acquired SCH found that *IDH1* p.R132C is found in at least 64% of cases³². Among cases negative for *IDH1* p.R132C, 20% had mutations at arginine 172 in exon 4 of *IDH2*, suggesting genetic heterogeneity³².

Mutations in exon 4 at arginine 132 of *IDH1* or at arginine 140 or 172 of *IDH2* lead to the production of 2-hydroxyglutarate, an oncometabolite which causes a hypermethylation phenotype leading to the inhibition of genes responsible for terminal differentiation^{33–36}. Additionally, mutations in *IDH1* found in gliomas lead to reduction of alpha-ketoglutarate production, inducing HIF-1 α , which drives tumor growth via the hypoxia pathway³⁷. Interestingly, analysis of HIF-1 α in SCH revealed a lack of expression in all samples³², suggesting that *IDH1* and *IDH2* mutations driving SCH may act via a distinct mechanism.

CAMTA1/TFE

Of childhood vascular tumors, epithelioid hemangioendothelioma (EHE) is the most common malignant variety. In 2001, Mendlick *et al.* reported an identical chromosomal translocation of t(1;3) (p36.3;q25) in two cases of EHE³⁸. Owing to low tumor cellularity and the absence of EHE cell lines, the specific genes disrupted via the translocation remained unknown until 2011, when Tanas *et al.* employed RNA sequencing to identify a

fusion between the promotor region of WW domain-containing transcription regulator 1 (*WWTR1*) on 3q25 and the carboxyl terminus of calmodulin-binding transcription activator 1 (*CAMTA1*) on 1p36³⁹. Given the high activity of the *WWTR1* promoter in endothelial cells and the ectopic expression of *CAMTA1*, which is typically found only in brain tissue, the authors hypothesized that *WWTR1/CAMTA1* functions as an oncogene via a promoter switch mechanism. Further work found that the *WWTR1-CAMTA1* fusion is a consistent genetic finding in EHEs of different anatomic subsites⁴⁰.

In EHE samples without a *WWTR1-CAMTA1* mutation, a distinct gene fusion between transcription factor E3 (*TFE3*) and yes-associated protein 1 (*YAPI*) was identified⁴¹. Given the structural and functional similarities between *YAPI* and *WWTR1* as well as the oncogenic nature of TFE3 with preserved transcriptional activation domains, well recognized in other cancers^{42–44}, a promoter switch similar to that of *WWTR1-CAMTA1* fusions is hypothesized to underlie oncogenesis in cases with *YAPI-TFE3* fusions.

GNA family

In recent years, a number of studies have highlighted the importance of the Ras–mitogen-activated protein kinase (MAPK) pathway in the oncogenic transformation of many childhood vascular tumors (Figure 1). The most upstream portion of the pathway elucidated thus far is the guanine nucleotide-binding protein subunit alpha q (G α q) family of genes: *GNAQ*, *GNA11*, and *GNA14*. In 2016, three studies demonstrated that somatic activating mutations in these genes are found in congenital hemangioma (including both rapidly involuting congenital hemangiomas and non-involuting congenital hemangiomas), kaposiform hemangioendotheliomas (KHEs), congenital tufted angiomas (TAs), and childhood lobular capillary hemangiomas (LCHs) via whole-exome sequencing^{45–47}. Activating mutations at the arginine 183 position of *GNA11* and the glutamine 209 position of *GNA11* and *GNAQ* were also found in several cases of sporadic congenital hemangioma, while mutation of glutamine 205 in *GNA14*, the analogous position of glutamine 209 in *GNA11* and *GNAQ*, was found in one case each of KHE, LCH, and TA^{45,46}. Recent work has also identified mutations in the glutamine 205 position of *GNA14* and the glutamine 209 position of *GNAQ* in anastomosing hemangiomas⁴⁸. Although these mutations have been demonstrated to cause cell morphology changes, upregulation of biochemical growth pathways, and acquisition of growth factor independence *in vitro*, they have not yet been shown to cause disease in an *in vivo* model. Notably, arginine 183 mutation in *GNAQ* is thought to be responsible for up to 88% of Sturge–Weber syndrome which presents with port-wine stains (PWSs) and leptomeningeal vascular malformations, while similar *GNA11* and *GNAQ* activating mutations underlie 77% of capillary malformations, 46% of uveal melanomas, and 83% of blue nevi^{49–52}. Activated GNA11 and GNAQ are thought to mediate VEGFR-2 phosphorylation, triggering human umbilical vein endothelial cell (HUVEC) proliferation *in vitro*⁵³.

These G α -subunit proteins exchange bound GDP for GTP when their associated G protein-coupled receptor (GPCR) is activated^{54,55}, leading to dissociation of the G-protein

Figure 1. Positions of the Ras-MAPK pathway wherein mutations have been demonstrated to lead to childhood vascular tumors (red arrows). Unbroken arrows indicate activation while broken arrows indicate migration.

heterotrimer—composed of G_α , G_β , and G_γ —from the GPCR and of the activated G_α subunit from the G_β/γ dimer, ultimately leading to the downstream activation of several cellular pathways.

The mechanism of tumorigenesis associated with these mutations can provide insights into targeted therapeutics. G_α is upstream of both the Ras-MAPK and the PI3K-Akt-mTOR, and previous studies of low-flow, lymphatic/venous, vascular malformations implicated the PI3K-Akt-mTOR pathway as the primary driver of these lesions^{56–59}. Although sirolimus is effective in the treatment of these low-flow lesions^{60–63}, it has shown little efficacy in vascular tumors, suggesting a distinct pathobiology^{62,64,65}. In a study using primary HUVECs expressing mutant *GNA11* and *GNA14*, cells showed no indication of PI3K-Akt-mTOR pathway activation (as measured by pAKT) and instead showed specific activation of the Ras-MAPK pathway (via increased pERK)⁴⁷, suggesting that a more effective therapy may involve targeting the Ras-MAPK pathway. Recent work suggests that high-flow arteriovenous malformations (AVMs) are also driven by mutations within the Ras-MAPK signaling pathway⁶⁶. Thus, advances in therapy for vascular tumors may also benefit patients with these high-flow vascular malformations. Somatic mutations in downstream components of this pathway in other vascular tumors further highlight the Ras-MAPK pathway as a primary driver of tumorigenesis in childhood vascular tumors.

The MAPK pathway

Activation of G_α leads to increased RAS activation⁶⁷. Indeed, a study of sporadic LCHs identified somatic mutations in all three subgroups of the RAS subfamily: *HRAS*, *KRAS*, and *NRAS*⁶⁸. The activating mutations, which mainly fall at codons 12, 13, and 61, have been established to generate constitutive Ras-MAPK signaling by preventing GTP hydrolysis⁶⁹. Furthermore, a study of LCHs arising within PWS also identified a p.V600E mutation in *BRAF*, a proto-oncogene directly downstream of Ras in the MAPK pathway chain⁷⁰. Interestingly, the study also found that both the underlying PWS and the LCH carried mutations in the arginine 183 position of *GNAQ* but that *BRAF* or *RAS* mutation was specific to the LCHs, suggesting that the LCHs arose because of a “second-hit” in *RAS* or *BRAF*.

Mutations in the Fos family of transcription factors, which are among the final components of the Ras-MAPK pathway, have also been identified in childhood vascular tumors. Cytogenetic study of pseudomyogenic hemangioendothelioma (PHE) revealed a t(7;19) (q22;q13) translocation as the sole anomaly in three lesions from one patient⁷¹. Later study of this patient and an additional case of PHE revealed that this translocation leads to a *SERPINE1-FOSB* fusion gene⁷². Although vascular endothelial cells demonstrate strong endogenous expression of *SERPINE1*, the *SERPINE1-FOSB* disrupts the protein-coding

portion of the *SERPINE1* gene, instead generating high levels of *FOSB* mRNA via a promoter switch mechanism^{72–74}. *FOSB* and *FOS* mutations have also been identified in cases of epithelioid hemangioma (EH). In one study of EH, Antonescu *et al.* identified two fusion genes: *WWTR1/FOSB* and *ZFP36/FOSB*⁷⁵. It has also been demonstrated that the *FOS* rearrangement leading to the truncation of the FOS protein, specifically to loss of the transactivation domain (TAD), leads to EH in bone.

Summary

The highlighted genetic discoveries in vascular tumor biology provide novel targets for therapeutics. Indeed, the fact that most of these mutations are present in known cancer-causing pathways means that many medications that are currently approved or under trial for other malignancies may be repurposed for use in vascular tumor therapy.

Mutations in *IDH* are known to cause gliomas, glioblastomas, chondrosarcomas, intrahepatic cholangiocarcinomas, and hematologic malignancies in addition to SCHs⁷⁶. As such, a number of therapeutics currently under investigation may also be effective in the treatment of SCH. Early results from trials of ivosidenib (AG-120), a novel inhibitor of mutant IDH1, in *IDH1*-mutated acute myelogenous leukemia (AML) indicated an overall response rate of 41.6% and a complete remission rate of 21.6%⁷⁷. Similarly, results from early trials of enasidenib (AG-221), a novel inhibitor of mutant IDH2, in *IDH2*-mutated AML indicated an overall response rate of 40.3% and a complete remission rate of 19.3%⁷⁸. These agents are currently under study in a number of clinical trials (ClinicalTrials.gov

Identifiers: NCT02074839, NCT02073994, NCT01915498, NCT02577406, NCT02632708, and NCT02677922). Mouse studies have also shown potential for an IDH1 peptide vaccine⁷⁹, which is currently under trial (ClinicalTrials.gov Identifiers: NCT02454634 and NCT02193347).

Selective inhibition of the Ras-MAPK pathway may provide a novel therapeutic avenue for childhood vascular lesions, which currently have few effective non-surgical options⁸⁰. The central role of this pathway in tumor pathobiology has necessitated the development of a number of currently available medications, including farnesyl transferase inhibitors such as salirasib, BRAF inhibitors such as vemurafenib, MEK inhibitors such as trametinib, and ERK inhibitors such as ulixertinib, which warrant further study as therapy for childhood vascular tumors. Indeed, Al-Olabi *et al.* demonstrated that treatment of AVMs in *BRAF*-mutant zebrafish with vemurafenib leads to restoration of blood flow in AVMs where it was previously limited⁸¹. With promising early results, these therapies hold great potential for the treatment of childhood vascular tumors.

Grant information

The work for this report was supported by the Leon Rosenberg, M.D., Medical Student Research Fund in Genetics and the Jane Danowski Weiss Family Foundation Fellowship at the Yale University School of Medicine.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Mulliken JB, Glowacki J: **Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics.** *Plast Reconstr Surg.* 1982; **69**(3): 412–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kanada KN, Merin MR, Munden A, *et al.*: **A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature.** *J Pediatr.* 2012; **161**(2): 240–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Walter JW, Blei F, Anderson JL, *et al.*: **Genetic mapping of a novel familial form of infantile hemangioma.** *Am J Med Genet.* 1999; **82**(1): 77–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Walter JW, North PE, Waner M, *et al.*: **Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.** *Genes Chromosomes Cancer.* 2002; **33**(3): 295–303.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Oszejka K, Szemraj J, Wyrzykowski D, *et al.*: **Single-nucleotide polymorphisms of *VEGF-A* and *VEGFR-2* genes and risk of infantile hemangioma.** *Int J Dermatol.* 2018; **57**(10): 1201–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
- Cheung DS, Warman ML, Mulliken JB: **Hemangioma in twins.** *Ann Plast Surg.* 1997; **38**(3): 269–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Castrén E, Salminen P, Viskula M, *et al.*: **Inheritance Patterns of Infantile Hemangioma.** *Pediatrics.* 2016; **138**(5): pii: e20161623.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
- Frieden IJ, Reese V, Cohen D: **PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities.** *Arch Dermatol.* 1996; **132**(3): 307–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Siegel DH, Shieh JTC, Kwon EK, *et al.*: **Copy number variation analysis in 98 individuals with PHACE syndrome.** *J Invest Dermatol.* 2013; **133**(3): 677–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Mitchell S, Siegel DH, Shieh JT, *et al.*: **Candidate locus analysis for PHACE syndrome.** *Am J Med Genet A.* 2012; **158A**(6): 1363–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Iacobas I, Burrows PE, Frieden IJ, *et al.*: **LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies.** *J Pediatr.* 2010; **157**(5): 795–801.e7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kleinman ME, Greives MR, Churgin SS, *et al.*: **Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma.** *Arterioscler Thromb Vasc Biol.* 2007; **27**(12): 2664–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Chang EI, Chang EI, Thangarajah H, *et al.*: **Hypoxia, Hormones, and Endothelial Progenitor Cells in Hemangioma.** *Lymphat Res Biol.* 2007; **5**(4): 237–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Barnés CM, Huang S, Kaipainen A, *et al.*: **Evidence by molecular profiling for a placental origin of infantile hemangioma.** *Proc Natl Acad Sci U S A.* 2005; **102**(52): 19097–102.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Barnés CM, Christison-Lagay EA, Folkman J: **The placenta theory and the origin of infantile hemangioma.** *Lymphat Res Biol.* 2007; **5**(4): 245–55.
[PubMed Abstract](#) | [Publisher Full Text](#)

16. Mihm MC Jr, Nelson JS: **Hypothesis: The metastatic niche theory can elucidate infantile hemangioma development.** *J Cutan Pathol.* 2010; **37** Suppl 1: 83–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. North PE, Waner M, Mizeracki A, *et al.*: **GLUT1: A newly discovered immunohistochemical marker for juvenile hemangiomas.** *Hum Pathol.* 2000; **31**(1): 11–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Greenberger S, Bischoff J: **Pathogenesis of infantile haemangioma.** *Br J Dermatol.* 2013; **169**(1): 12–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Boye E, Yu Y, Paranya G, *et al.*: **Clonality and altered behavior of endothelial cells from hemangiomas.** *J Clin Invest.* 2001; **107**(6): 745–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Boscolo E, Stewart CL, Greenberger S, *et al.*: **JAGGED1 Signaling Regulates Hemangioma Stem Cell-to-Pericyte/Vascular Smooth Muscle Cell Differentiation.** *Arterioscler Thromb Vasc Biol.* 2011; **31**(10): 2181–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Wu JK, Adepoju O, De Silva D, *et al.*: **A switch in Notch gene expression parallels stem cell to endothelial transition in infantile hemangioma.** *Angiogenesis.* 2010; **13**(1): 15–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Boscolo E, Mulliken JB, Bischoff J: **Pericytes from infantile hemangioma display proangiogenic properties and dysregulated angiopoietin-1.** *Arterioscler Thromb Vasc Biol.* 2013; **33**(3): 501–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Wassef M, Blei F, Adams D, *et al.*: **Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies.** *Pediatrics.* 2015; **136**(1): e203–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, *et al.*: **A randomized, controlled trial of oral propranolol in infantile hemangioma.** *N Engl J Med.* 2015; **372**(8): 735–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. **F** Izadpanah A, Izadpanah A, Kanevsky J, *et al.*: **Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis.** *Plast Reconstr Surg.* 2013; **131**(3): 601–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
26. Price CJ, Lattouf C, Baum B, *et al.*: **Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis.** *Arch Dermatol.* 2011; **147**(12): 1371–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Pandey A, Gangopadhyay AN, Gopal SC, *et al.*: **Twenty years' experience of steroids in infantile hemangioma—a developing country's perspective.** *J Pediatr Surg.* 2009; **44**(4): 688–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. North PE, Waner M, Mizeracki A, *et al.*: **A unique microvascular phenotype shared by juvenile hemangiomas and human placenta.** *Arch Dermatol.* 2001; **137**(5): 559–70.
[PubMed Abstract](#)
29. Huang L, Nakayama H, Klagsbrun M, *et al.*: **Glucose Transporter 1-Positive Endothelial Cells in Infantile Hemangioma Exhibit Features of Facultative Stem Cells.** *Stem Cells.* 2015; **33**(1): 133–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Pansuriya TC, Kroon HM, Bovée JV: **Enchondromatosis: insights on the different subtypes.** *Int J Clin Exp Pathol.* 2010; **3**(6): 557–69.
[PubMed Abstract](#) | [Free Full Text](#)
31. Pansuriya TC, van Eijk R, d'Adamo P, *et al.*: **Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome.** *Nat Genet.* 2011; **43**(12): 1256–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Kurek KC, Pansuriya TC, van Ruler MA, *et al.*: **R132C IDH1 mutations are found in spindle cell hemangiomas and not in other vascular tumors or malformations.** *Am J Pathol.* 2013; **182**(5): 1494–500.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. **F** Dang L, White DW, Gross S, *et al.*: **Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.** *Nature.* 2009; **462**(7274): 739–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
34. **F** Lu C, Ward PS, Kapoor GS, *et al.*: **IDH mutation impairs histone demethylation and results in a block to cell differentiation.** *Nature.* 2012; **483**(7390): 474–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
35. **F** Figueroa ME, Abdel-Wahab O, Lu C, *et al.*: **Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.** *Cancer Cell.* 2010; **18**(6): 553–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
36. **F** Turcan S, Rohle D, Goenka A, *et al.*: **IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.** *Nature.* 2012; **483**(7390): 479–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
37. **F** Zhao S, Lin Y, Xu W, *et al.*: **Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.** *Science.* 2009; **324**(5924): 261–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
38. Mendlick MR, Nelson M, Pickering D, *et al.*: **Translocation t(1;3)(p36.3;q25) is a nonrandom aberration in epithelioid hemangioendothelioma.** *Am J Surg Pathol.* 2001; **25**(5): 684–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Tanas MR, Sboner A, Oliveira AM, *et al.*: **Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma.** *Sci Transl Med.* 2011; **3**(98): 98ra82.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Errani C, Zhang L, Sung YS, *et al.*: **A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites.** *Genes Chromosomes Cancer.* 2011; **50**(8): 644–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Antonescu CR, Le Loarer F, Mosquera JM, *et al.*: **Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma.** *Genes Chromosomes Cancer.* 2013; **52**(8): 775–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Sidhar SK, Clark J, Gill S, *et al.*: **The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene.** *Hum Mol Genet.* 1996; **5**(9): 1333–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Clark J, Lu YJ, Sidhar SK, *et al.*: **Fusion of splicing factor genes PSF and NonO (p54^{nbs}) to the TFE3 gene in papillary renal cell carcinoma.** *Oncogene.* 1997; **15**(18): 2233–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Ladanyi M, Lui MY, Antonescu CR, *et al.*: **The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.** *Oncogene.* 2001; **20**(1): 48–57.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Funk T, Lim Y, Kulungowski AM, *et al.*: **Symptomatic Congenital Hemangioma and Congenital Hemangiomatosis Associated With a Somatic Activating Mutation in GNA11.** *JAMA Dermatol.* 2016; **152**(9): 1015–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. **F** Ayturk UM, Couto JA, Hann S, *et al.*: **Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma.** *Am J Hum Genet.* 2016; **98**(4): 789–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
47. Lim YH, Bacchiocchi A, Qiu J, *et al.*: **GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation.** *Am J Hum Genet.* 2016; **99**(2): 443–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. **F** Bean GR, Joseph NM, Folpe AL, *et al.*: **Recurrent GNA14 mutations in anastomosing haemangiomas.** *Histopathology.* 2018; **73**(2): 354–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
49. Nakashima M, Miyajima M, Sugano H, *et al.*: **The somatic GNAQ mutation c.548G>A (p.R183Q) is consistently found in Sturge-Weber syndrome.** *J Hum Genet.* 2014; **59**(12): 691–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. **F** Couto JA, Huang L, Vivero MP, *et al.*: **Endothelial Cells from Capillary Malformations Are Enriched for Somatic GNAQ Mutations.** *Plast Reconstr Surg.* 2016; **137**(1): 77e–82e.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
51. **F** Van Raamsdonk CD, Bezrookove V, Green G, *et al.*: **Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.** *Nature.* 2009; **457**(7229): 599–602.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
52. **F** Shirley MD, Tang H, Gallione CJ, *et al.*: **Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ.** *N Engl J Med.* 2013; **368**(21): 1971–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
53. Zeng H, Zhao D, Yang S, *et al.*: **Heterotrimeric G alpha q/G alpha 11 proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling.** *J Biol Chem.* 2003; **278**(23): 20738–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Wettschurek N, Offermanns S: **Mammalian G proteins and their cell type specific functions.** *Physiol Rev.* 2005; **85**(4): 1159–204.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Hubbard KB, Hepler JR: **Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins.** *Cell Signal.* 2006; **18**(2): 135–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Morris PN, Dunmore BJ, Tadros A, *et al.*: **Functional analysis of a mutant form of the receptor tyrosine kinase Tie2 causing venous malformations.** *J Mol Med (Berl).* 2005; **83**(1): 58–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Osborn AJ, Dickie P, Neilson DE, *et al.*: **Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations.** *Hum Mol Genet.* 2015; **24**(4): 926–38.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Limaye N, Kangas J, Mendola A, *et al.*: **Somatic Activating PIK3CA Mutations Cause Venous Malformation.** *Am J Hum Genet.* 2015; **97**(6): 914–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Luks VL, Kamitaki N, Vivero MP, *et al.*: **Lymphatic and other vascular**

- malformative/overgrowth disorders are caused by somatic mutations in *PIK3CA*. *J Pediatr*. 2015; **166**(4): 1048–54.e1–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. **F** Hammill AM, Wentzel M, Gupta A, *et al.*: Sirolimus for the treatment of complicated vascular anomalies in children. *Pediatr Blood Cancer*. 2011; **57**(6): 1018–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 61. Yuksekkaya H, Ozbek O, Keser M, *et al.*: Blue rubber bleb nevus syndrome: successful treatment with sirolimus. *Pediatrics*. 2012; **129**(4): e1080–e1084.
[PubMed Abstract](#) | [Publisher Full Text](#)
 62. **F** Triana P, Dore M, Cerezo VN, *et al.*: Sirolimus in the Treatment of Vascular Anomalies. *Eur J Pediatr Surg*. 2017; **27**(1): 86–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 63. Boscolo E, Limaye N, Huang L, *et al.*: Rapamycin improves *TIE2*-mutated venous malformation in murine model and human subjects. *J Clin Invest*. 2015; **125**(9): 3491–504.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 64. **F** Adams DM, Trenor CC 3rd, Hammill AM, *et al.*: Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. *Pediatrics*. 2016; **137**(2): e20153257.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 65. Lackner H, Karastaneva A, Schwinger W, *et al.*: Sirolimus for the treatment of children with various complicated vascular anomalies. *Eur J Pediatr*. 2015; **174**(12): 1579–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. **F** Couto JA, Huang AY, Konczyk DJ, *et al.*: Somatic *MAP2K1* Mutations Are Associated with Extracranial Arteriovenous Malformation. *Am J Hum Genet*. 2017; **100**(3): 546–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 67. Kwan DH, Yung LY, Ye RD, *et al.*: Activation of Ras-dependent signaling pathways by G_{i4} -coupled receptors requires the adaptor protein TPR1. *J Cell Biochem*. 2012; **113**(11): 3486–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Lim YH, Douglas SR, Ko CJ, *et al.*: Somatic Activating *RAS* Mutations Cause Vascular Tumors Including Pyogenic Granuloma. *J Invest Dermatol*. 2015; **135**(6): 1698–700.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 69. Bos JL: ras oncogenes in human cancer: a review. *Cancer Res*. 1989; **49**(17): 4682–9.
[PubMed Abstract](#)
 70. **F** Groesser L, Peterhof E, Evert M, *et al.*: *BRAF* and *RAS* Mutations in Sporadic and Secondary Pyogenic Granuloma. *J Invest Dermatol*. 2016; **136**(2): 481–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 71. Trombetta D, Magnusson L, von Steyern FV, *et al.*: Translocation *t(7;19)(q22;q13)*—a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma? *Cancer Genet*. 2011; **204**(4): 211–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Walther C, Tayebwa J, Liljebjörn H, *et al.*: A novel *SERPINE1-FOSB* fusion gene results in transcriptional up-regulation of *FOSB* in pseudomyogenic hemangioendothelioma. *J Pathol*. 2014; **232**(5): 534–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
 73. Simpson AJ, Booth NA, Moore NR, *et al.*: Distribution of plasminogen activator inhibitor (*PAI-1*) in tissues. *J Clin Pathol*. 1991; **44**(2): 139–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 74. Declercq PJ, Gils A: Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. *Semin Thromb Hemost*. 2013; **39**(4): 356–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
 75. Antonescu CR, Chen HW, Zhang L, *et al.*: *ZFP36-FOSB* fusion defines a subset of epithelioid hemangioma with atypical features. *Genes Chromosomes Cancer*. 2014; **53**(11): 951–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 76. **F** Mondesir J, Willekens C, Touat M, *et al.*: *IDH1* and *IDH2* mutations as novel therapeutic targets: current perspectives. *J Blood Med*. 2016; **7**: 171–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 77. **F** DiNardo CD, Stein EM, de Botton S, *et al.*: Durable Remissions with Ivosidenib in *IDH1*-Mutated Relapsed or Refractory AML. *N Engl J Med*. 2018; **378**(25): 2386–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 78. **F** Stein EM, DiNardo CD, Pollyea DA, *et al.*: Enasidenib in mutant *IDH2* relapsed or refractory acute myeloid leukemia. *Blood*. 2017; **130**(6): 722–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 79. **F** Schumacher T, Bunse L, Pusch S, *et al.*: A vaccine targeting mutant *IDH1* induces antitumour immunity. *Nature*. 2014; **512**(7514): 324–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 80. Wine Lee L, Goff KL, Lam JM, *et al.*: Treatment of pediatric pyogenic granulomas using β -adrenergic receptor antagonists. *Pediatr Dermatol*. 2014; **31**(2): 203–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 81. **F** Al-Olabi L, Polubothu S, Dowsett K, *et al.*: Mosaic *RAS*/*MAPK* variants cause sporadic vascular malformations which respond to targeted therapy. *J Clin Invest*. 2018; **128**(11): 5185.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Douglas A. Marchuck**

Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, USA

Competing Interests: No competing interests were disclosed.

2. **Joyce Bischoff**

Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research